Nucleotyping

DNA Image Ploidy

Background description
Cancers are associated with large-scale genomic instability. DNA-Ploidy provides an objective display of the distribution of DNA contents in a tissue-sample. This helps the pathologist with detecting this genomic instability at an early stage. DNA Ploidy is based on well researched and proven technologies. An advanced system has been developed in collaboration with the RR HF (Oslo, Norway) and the management of Room4.

Video showing system in operation click here.

Please contact us for more infomation. Email

Benefits of DNA Image Ploidy

DNA Ploidy is becoming an accepted prognostic marker, and the cost of DNA Ploidy tests are covered by health insurance schemes in the UK, Norway, Sweden and France. In the US some health insurance companies will reimburse the cost of flow-cytometry, an independency proven less accurate method of completing DNA Ploidy test when compared to the image based method discussed here. As the DNA Ploidy test alone when used to obtain prognostic information to determine treatment decisions in prostatic, urinary bladder, ovarian, endometrial and renal cell carcinoma among others. DNA Ploidy provides a cost effective and objective way to assess the progression and treatment decisions.

The most precise, complete and fastest image-based DNA Ploidy system on the market, designed with the clinical user in mind
Better prognostic information value
A reliable and thoroughly validated technology used in the medical world

The System

The system comprises a research microscope automation hardware a, high quality digital camera and software. Automated object capture, cell type classification and DNA Ploidy classification.

Selected DNA ploidy references:

Baak JP, Snijders W, van Diermen B, van Diest PJ, Diepenhorst FW, Benraadt J. Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma. J Clin Oncol. 2003 Nov 15;21(22):4214-21.
Araujo SE, Bernardo WM, Habr-Gama A, Kiss DR, and Cecconello I. DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum, 50: 1800-1810, 2007
Walther A, Houlston R, and Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut, 57: 941-950, 2008.
Choma D, Daures JP, Quantin X, and Pujol JL. Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. Br J Cancer, 85: 14-22, 2001
Gazic B, Pizem J, Bracko M, Cufer T, Borstnar S, Pohar-Marinsek Z, and Us-Krasovec M. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients. Cytopathology, 19: 294-302, 2008.
Bergers E, Baak JP, van Diest PJ, Willig AJ, Los J, Peterse JL, Ruitenberg HM, Schapers RF, Somsen JG, van Beek MW, Bellot SM, Fijnheer J, van Gorp LH. Prognostic value of DNA ploidy using flow cytometry in 1301 breast cancer patients: results of the prospective Multicenter Morphometric Mammary Carcinoma Project. Mod Pathol. 1997 Aug;10(8):762-8.
Tropé C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, Onsrud M, Pettersen E, Rosenberg P, Sandvei R, Sundfor K, Vergote I. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument.
Ann Oncol. 2000 Mar;11(3):281-8.
Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Tropé CG, Danielsen HE. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.
Ann Oncol. 2003 Oct;14(10):1494-500.
Pretorius ME, Waehre H, Abeler VM, Davidson B, Vlatkovic L, Lothe RA, Giercksky KE, Danielsen HE. Large scale genomic instability as an additive prognostic marker in early prostate cancer.
Cell Oncol. 2009;31(4):251-9.